Purpose Women diagnosed with breast cancer have heterogeneous survival outcomes that cannot be fully explained by known prognostic factors, and germline variation is a plausible but unconfirmed risk factor. Methods We used three approaches to test the hypothesis that germline variation drives some differences in survival: mortality loci identification, tumor aggressiveness loci identification, and whole-genome prediction. The 2954 study participants were women diagnosed with breast cancer before age 50, with a median follow-up of 15 years who were genotyped on an exome array. We first searched for loci in gene regions that were associated with all-cause mortality. We next searched for loci in gene regions associated with five histopathological characteristics related to tumor aggressiveness. Last, we also predicted 10-year all-cause mortality on a subset of 1903 participants (3,245,343 variants after imputation) using whole-genome prediction methods.
Abstract Purpose Women diagnosed with breast cancer have heterogeneous survival outcomes that cannot be fully explained by known prognostic factors, and germline variation is a plausible but unconfirmed risk factor. Methods We used three approaches to test the hypothesis that germline variation drives some differences in survival: mortality loci identification, tumor aggressiveness loci identification, and whole-genome prediction. The 2954 study participants were women diagnosed with breast cancer before age 50, with a median follow-up of 15 years who were genotyped on an exome array. We first searched for loci in gene regions that were associated with all-cause mortality. We next searched for loci in gene regions associated with five histopathological characteristics related to tumor aggressiveness. Last, we also predicted 10-year all-cause mortality on a subset of 1903 participants (3, 245 ,343 variants after imputation) using whole-genome prediction methods.
Results No risk loci for mortality or tumor aggressiveness were identified. This null result persisted when restricting to women with estrogen receptor-positive tumors, when examining suggestive loci in an independent study, and when restricting to previously published risk loci. Additionally, the whole-genome prediction model also found no evidence to support an association. Conclusion Despite multiple complementary approaches, our study found no evidence that mortality in women with early onset breast cancer is influenced by germline variation.
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Introduction
While treatment and survival rates for women diagnosed with breast cancer have improved over time [1] , almost 25% of the 250,000 American women who are diagnosed with breast cancer annually eventually die of the disease [2, 3] . Mortality in women with breast cancer is associated with several factors, including stage at detection, socioeconomic factors, tumor characteristics, and treatment decisions [4, 5] . However, after taking these into account, differences in survival persist [4] . Several lines of evidence, including animal and epidemiological studies [6] [7] [8] , suggest that germline genetic variation may influence the unexplained heterogeneity in mortality.
Identifying locations in the genome in which variation is associated with mortality can implicate cellular processes that are involved in oncoprogression, and may suggest targets for future pharmaceutical interventions. However, since there are many biologically plausible pathways that connect germline variation and mortality, and any single method may not be optimal to identify all regions of the genome that influence mortality trajectories. If the putative mortality-associated variant is common in the general population and has a moderately strong effect, it can often be identified through single-marker regression approaches common in genome-wide association studies (GWAS). Several GWASs have been published that investigated associations with breast cancer mortality (summarized in supplemental text), but the results have largely been null or poorly replicated. Most studies were small (all but one meta-analysis recruited fewer than 2000 participants), and were only able to follow women for a short period of time relative to the expected median survival of women after breast cancer diagnosis (none were followed longer than 7 years). In contrast to GWASs, gene-based tests such as the sequence kernel association test-optimal (SKAT-O [9] ) use a different approach and allow variants within a gene region to collectively contribute evidence for association, even if the putative variant is too rare to be tested individually, or has an effect that is too small to be detected with the strict significance thresholds necessitated by GWASs. No breast cancer mortality study has reported the results of gene-based tests genome-wide.
In addition to identifying individual loci that are associated with mortality, it is also of clinical interest to predict mortality in women with breast cancer to better identify those who may want to choose aggressive treatment, and also women who may more confidently choose to forgo toxic therapies [10] . Previous studies have attempted to incorporate germline variation into prediction models of breast cancer mortality using both candidate gene and polygenic risk score approaches; these models have produced mixed results [11, 12] . If mortality in women with breast cancer is a polygenic trait, genetic restricted maximum likelihood prediction methods [13] , which allow all measured genetic variation to contribute to prediction without excluding variants that meet effect size thresholds, may improve upon these other method's ability to predict mortality, but this has not yet been applied to studies of breast cancer mortality.
The largely null and inconsistent results from previous studies suggest the hypothesis that germline variation is not strongly associated with mortality in women who have been diagnosed with breast cancer. The objective of this manuscript is to look for evidence that germline variation influences mortality in women with breast cancer by applying single-marker regressions, gene-based tests, and whole-genome prediction to a sample of women diagnosed with breast cancer before the age of fifty. The primary outcome of interest is all-cause mortality, and we also considered histopathological markers of tumor aggressiveness as secondary outcomes.
Materials and methods

Participants
The participants were enrolled in one of five studies originally designed to assess the factors associated with early onset breast cancer incidence and prognosis, summarized in supplemental Table 3 . The participants were women of European descent without pathogenic mutations in the BRCA1 or BRCA2 genes. Ninety-eight percent were younger than 50 years at the time of their diagnosis. Details of recruitment and data collection are found in the supplemental text.
Any suggestive findings from the primary analyses were examined for evidence of replication in data provided by the participants of The Cancer Genome Atlas (TCGA [14]) breast cancer study. Single nucleotide variant (SNV) data were downloaded from the TCGA data portal in June 2015, and clinical data were downloaded in September 2016.
Genotyping
Details of the genotyping, imputation, and quality control are found in the supplemental text and in supplemental Figs. 1 and 2 .
Briefly, for the 3232 participants enrolled in the primary studies, germline DNA was extracted from peripheral blood. All were genotyped on the Illumina HumanExome 12v1 exome array (238,524 variants). If the variant passed variant-level quality control (4335 variants excluded), was polymorphic in this population (135,931 included), and located in a gene region (i.e., excluding intergenic variants, as annotated by ANNOVAR [15]), it was included in the mortality loci identification analyses (114,206 included). The quality control also excluded 278 women, resulting in 2954 women available for these analyses.
Of the 3232 women genotyped on the exome array, a subset of 2323 was additionally genotyped using the Illumina 610-Quad and Cyto12 v2 BeadChips (555,259 variants interrogated; 3,310,158 variants after imputation to the HapMap3 [16] ). The quality control process excluded 325 women with either no survival information or who did not pass QC (1998 women available). The exome and genomewide variants were combined (3,245,343 variants).
The TCGA data included the 768 participants of the TCGA breast cancer study who were females of European ancestry. After quality control and imputation (details in supplemental text) to the 1000 Genomes phase 3 [17] , 711 women and 15,121,555 variants were available for replication.
Primary outcome: all-cause mortality All-cause mortality was determined within each study through chart review, telephone interviews, linkage to cancer registries, and linkage mortality databases.
Statistical approach for identifying mortality risk loci
To identify variants or gene regions associated with the hazard of all-cause mortality, both single-marker regression GWASs and gene-based SKAT-O Cox proportional hazards models were applied to the 2954 women who were assayed on the exome array. The GWASs were implemented using the GenABEL [18, 19] package for the R software. Only common variants on the exome array were included in the GWASs (minor allele frequency above the threshold of (1/2n) 1/2 = 0.0130 following Wu et al. [20] ; 25,938 variants). The SKAT-O analyses were implemented using the skatMeta R package [21] , after annotation to 16,317 genes by ANNOVAR. Each variant was weighted by the combined annotation-dependent depletion (CADD) [22] scaled score of the predicted deleteriousness of the minor allele. The twenty variants or genes with the smallest p value in the primary analyses were examined for evidence of replication in the TCGA data.
The relationship between germline variation and mortality in women with estrogen receptor-positive (ER?) tumors was of particular interest due to a plausible but unconfirmed pharmacogenomic pathway to mortality. During the period that the women in this study were diagnosed, approximately 80% of those with ER? tumors would have been treated with tamoxifen [23, 24] , whose active metabolites are known to be influenced by germline variation. It is unclear whether this influences survival, and there has been conflicting evidence specifically on the effect of variation within the tamoxifen-metabolizing gene CYP2D6 on survival [25] [26] [27] . To investigate this, both analyses were repeated after restricting to the women known to have ER? tumors (n = 1066). Given the low rates of replication of previously identified mortality risk loci, it was also of interest to examine whether our analyses provided evidence of replication. The National Human Genome Research Institute-European Bioinformatics Institute (NHGRI-EBI) GWAS catalog [28] was searched in January 2017 and variants identified with breast cancer mortality were identified. Genes containing these variants were examined in our analysis.
Additionally, it is not known whether risk loci that are associated with other breast cancer phenotypes may also be associated with mortality. If that were the case, it would suggest a shared genetic etiology between the other breast cancer phenotypes (primarily breast cancer incidence, but also mammographic density, and other breast tissue characteristics) and mortality. To look for evidence of this, the variants listed in the NHGRI-EBI catalog as being associated with any breast cancer phenotype were examined in our analysis if the p value of that variant was genome-wide significant (p \ 5 9 10 -8 ).
Statistical approach for whole-genome prediction of 10-year mortality
Of the 1998 women with exome and genome-wide assays, 1903 had complete survival information for 10 years after diagnosis and were included. Of these, 400 (27%) died within 10 years of diagnosis. This 10-year mortality status was predicted using the R package OmicKriging [13] , and the genetic relatedness matrix was created using all 3,245,343 variants by the GCTA software [29] . Using tenfold cross-validation, the Kriging formula estimated a linear predicted probability of mortality for each woman. These predictions were compared to that woman's actual mortality status to compute an area under the receiver operating characteristic (AUC). This procedure was repeated two hundred times to produce valid confidence intervals for the AUC.
Secondary outcome: tumor characteristics
Molecular and histopathological properties of the tumor are evaluated at diagnosis, and women with more aggressive tumor profiles generally have worse survival trajectories [30, 31] . To identify loci that are associated with any of the more aggressive tumor profiles, five logistic regressions were run to examine whether germline variation in gene regions could predict ER status, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, high tumor grade (three or higher), or high tumor stage (three or higher) using the SKAT package for R [9] . ER status was available for 1785 women, PR status for 1769, HER2 status for 658, tumor grade for 1790, and tumor stage for 1640.
Covariates used in the mortality risk loci identification analyses
To counter the potential confounding between genetic ancestry and mortality, principal components constructed from both common and rare variants were also included as covariates in each single-marker regression and gene-based analysis. Details of the selection of the principal components are in the supplemental text. Study center was additionally included as a covariate.
Results
The characteristics of the women that were included in each investigation after quality control are given in Table 1 .
Common variants in gene regions and all-cause mortality: single-marker regression
The single-marker regressions identified no common variants that were associated with mortality with a p value smaller than the Bonferroni-corrected significance level of 1.8 9 10 -6 either in all women with breast cancer, or those with ER? tumors. Quantile-quantile (QQ) plots of the association results are found in Fig. 1A, B . None of the twenty most significant variants in the primary analyses were associated with mortality in the TCGA analysis with a p value smaller than Bonferroni-corrected significance level of 0.0025 (supplemental Tables 4 and 5) .
Twenty-three SNVs listed in the NHGRI-EBI GWAS catalog as significantly associated with any breast cancer phenotype were directly interrogated by the exome array. None had a p value less than the Bonferroni-corrected level of 0.05/23 = 0.0022 in either the overall or ER? only analysis, as shown in supplemental Table 6 .
Gene regions and all-cause mortality: gene-based tests
The gene-based tests identified no gene regions in which variation was associated with the hazard of mortality either in all women, or those with ER? tumors with a p value smaller than the Bonferroni-corrected significance level of 3.06 9 10 -6 QQ plots are shown in Fig. 2A and B. None of the twenty gene regions with the smallest p values in the primary analyses were associated with mortality in the TCGA population with a p value smaller 0.0025 in the TCGA analysis (supplemental Tables 7 and 8 ). To determine if the results were sensitive to the weighting method, the analyses were repeated using weights that were a beta transformation of the minor allele frequency (as suggested by the SKAT authors [9] ), and equal weights. These two additional weighting methods produced substantively similar null results.
We measured four nonsynonymous SNVs within the gene CYP2D6 on chromosome 22 (positions in the HG19 assembly: 42523844, 42523855, 42523975, 42524817), and found no evidence of association between these SNVs and mortality either in all women (p = 7.81 9 10 -2 ) or in women with ER? tumors (p = 7.75 9 10 -1 ). The NHGRI-EBI GWAS catalog lists variants in five gene regions that were also interrogated by the exome array as associated with breast cancer mortality. None of the genes were statistically significant in either mortality analysis (supplemental Table 9 ).
The NHGRI-EBI GWAS catalog lists variants in fiftythree assayed gene regions that were significantly associated with any breast cancer phenotype. Of these, none were associated with mortality with a p value smaller than Bonferroni-corrected significance level for replication of previously identified loci of p \ 0.05/53 = 9.43 9 10 -4 (supplemental Tables 10 and 11 ).
Gene regions and tumor characteristics: gene-based tests
No associations with any of the five characteristics of tumor aggressiveness reached the level of genome-wide significance, and the TCGA data did not provide any evidence of replication for twenty gene regions with the smallest p value in the primary analyses (Fig. 2C-G , and  supplemental Tables 12-16 ).
The p values of the variants in the breast cancer gene regions highlighted in the NHGRI-EBI catalog for each tumor characteristic are summarized in supplemental Tables 17 and 18 ). Only one gene in the tumor characteristic analyses met a Bonferroni-corrected threshold of significance for replication of the previous loci: SLC4A7 (p = 8.35 9 10 -4 for PR status). A variant located at chromosome 3:27416013 (the three prime untranslated region of SLC4A7) was reported in one previous study (p = 2 9 10 -8 ) [32] , and one meta-analysis which included that original study (p = 2 9 10 -30 ) [33] as being associated with breast cancer incidence in women of European descent. Variants in the adjacent gene of NEK10 were previously associated with incidence, both in our own analysis (under review) and previous studies [34, 35] .
Ten-year mortality: whole-genome prediction
The AUC of the whole-genome prediction was not significantly different than chance (AUC: 0.493, 95% CI 0.479-0.510). The performance of Kriging prediction has a 547 cases in the prediction analysis died during the follow-up period, however, the prediction analysis used 10-year mortality as an outcome. 400 of the deaths occurred prior to 10 years post-diagnosis been shown to improve if separate genetic relatedness matrices are constructed that group variants with similar association strengths together [13] . For this reason, the Kriging was repeated with multiple matrices three times: separating variants into two matrices based on rareness (minor allele frequency above and below 0.0127), three matrices based on their predicted functionality (annotation by ANNOVAR into (1) intergenic (2) gene regions, but no change to amino acid translation, and (3) predicted to change amino acid translation), and the six matrices that represented the cross-product of variant rareness and predicted functionality. In each of these models, the null result persisted. For comparison, GCTA was used to estimate the proportion of variation in 10-year mortality that was associated with genotypic variation (''heritability'') using a single genetic relatedness matrix with all 3,245,343 variants. The heritability estimate was near zero with a large standard error (estimate: 0.000002, standard error: 0.2). Also for comparison, a polygenic risk score prediction was undertaken using the 81 SNVs that were measured in either the exome array or genome-wide array and listed in the NHGRI-EBI GWAS catalog as associated with any breast cancer phenotype. The predictive power of this polygenic risk score was also not different from chance (AUC 0.484; 95% CI from 2000 bootstrap replications: 0.453-0.516).
Discussion
Multiple complementary analyses found no evidence that mortality in women diagnosed with breast cancer is influenced by germline variation. Our analysis included singlemarker regressions and gene-based tests of mortality and markers of tumor aggressiveness, and also whole-genome prediction, heritability estimates, and polygenic risk score analyses of mortality. Each has its own limitations, but each returned null results. When combined with our inability to confirm the mortality risk loci identified by previous GWASs, this suggests that unlike breast cancer incidence [36] , mortality in women diagnosed with breast cancer may not be strongly influenced by germline variation.
Our study represents the first us of several methods to investigate mortality in women with breast cancer, which we hypothesized would capture associations that may have been missed by previous research. We directly investigated for the first time the role of rare exonic variants, and were the first to use gene-based tests. While restricted to variants within gene regions, the results of our single-marker regressions were the longest follow-up in a GWAS of mortality in breast cancer. Our prediction model was also the first to incorporate the influence of all germline variation.
Our sample included women who were diagnosed with breast cancer before age 50, and is the first genome-wide investigation of mortality that specifically targeted this young age group. This provided a unique insight into the survival trajectory of the one in five American women with breast cancer who are diagnosed that early [3] . Although recent work suggested that the genetic etiology of breast cancer incidence may be similar across ages of diagnosis [34] , the full relationship between age and genetic etiology of breast cancer is still not well characterized. Therefore, the generalizability of these null results to women who were diagnosed later in life is yet to be established.
Our analysis did not find that gene regions that had been reproducibly associated with breast cancer incidence were also associated with mortality, suggesting a separate genetic etiology of incidence and mortality in breast cancer. To a large extent, the analysis did not support the hypothesis that incidence risk loci are associated with characteristics of tumor aggressiveness. One gene that contained a previous incidence risk locus, SLC4A7/NEK10, was associated with the PR status of the tumor in our analysis with a p value that was slightly smaller the Bonferroni-corrected threshold, but the borderline significance of this association should be interpreted cautiously in light of the multiple hypotheses tested.
Our analysis focused on all-cause mortality. While this decision allowed for germline variation to beyond breast cancer-specific mortality (for example, susceptibility to cardiotoxic side effects from chemotherapy), it is possible that our analysis obscured associations with cause-specific mortality. While a sensitivity analysis would have been preferable, in our sample, breast cancer-specific mortality was not available for all participants.
Previous epidemiologic and animal studies suggested that germline variation does influence mortality in women with breast cancer [6] [7] [8] . While the discrepancy between past work and ours may be due to study design (many of the epidemiologic studies were carried out using a familybased design, which may be prone to bias from shared environment), our results do not rule out the possibility that genetic variation influences mortality. However, our results do suggest possible constraints on the genetic architecture of that association. If mortality were driven by variants that were not in strong linkage disequilibrium with any variants measured by the two array-based methods used here, these analyses would have limited ability to detect their association. While whole-genome sequencing would have mitigated this concern, the exome and genome-wide arrays selected for use in this study were designed to well-interrogate much of the genome in people of European descent, and therefore, only variants with a low frequency would have been likely to have gone unmeasured. Thus, our results suggest that if germline variation were associated with survival in women with breast cancer, it would likely be characterized by one of two descriptions: large effect size, but so rare as to not have much effect on overall mortality, or small effect size.
If the putative variants have a large effect size, this suggests that family-based studies would be more appropriate than GWASs to identify them. If the putative variants have a small effect size (SKAT power calculations estimated we achieved 80% power in our sample size when detecting an association with a hazard ratio of 2.1, although our study may have lost power due to our replication data not fully matching our primary analyses), they would be very difficult to detect. The identification of such variants may be unlikely to highlight mechanisms that are necessary or sufficient for mortality in women with breast cancer, and even the cumulative influence of multiple such variants would be unlikely to add to our ability to identify high-risk women with breast cancer at the population level.
Our findings suggest that future investment into studying the inherited nature of mortality in women with breast cancer may be most fruitful if it focuses on interaction analyses. This approach may identify germline variants that affect survival trajectories for a subset of women, by focusing on women where this association is already suggested, or focusing on women who have not been wellrepresented in survival studies to date. For example, recent research has suggested that other germline genetic variants may be associated with mortality in women with pathogenic mutations in the genes BRCA2 and TP53 [37, 38] . Beyond gene-by-gene interactions, germline variation may have a larger influence on breast cancer mortality in populations that have different background risk factors such as ancestry (this sample was of European ancestry), or country of origin (this sample was recruited from affluent countries). Germline variation may also influence mortality by way of an interaction with treatment [39] , which was not consistently available for our participants. Given the young age at diagnosis, the participants may have been treated more aggressively, compared to those diagnosed at a later age who may have had more comorbidities, and it is possible that germline variation has less of an impact on survival in the presence of aggressive surgery or treatment.
In conclusion, while germline genetic variation may still be associated with survival trajectories in women with early onset breast cancer, our multi-approach study was unable to find evidence of this in our sample.
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